Nasdaq
$1.12▼ 1.32%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $12.9MShares out 11.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 5d agoRegular26.10.20 03:27SCHEDULE 13GOwnership#●●●
Bionano Genomics, Inc.
Orin Hirschman has been newly reported as a major shareholder of Bionano Genomics, Inc., holding more than 5% of the company's shares. This disclosure was made via a Schedule 13G filing submitted on October 19, 2026.…more
$1.12-1.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14Pre-market26.09.14 21:308-KKey event
Bionano Genomics, Inc.
Bionano Genomics presented its clinical adoption progress of Optical Genome Mapping (OGM) and financial performance at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company reported Q2 2026 revenue of $8.2 million, exceeding its guidance, and outlined a long-term growth plan targeting adjusted EBITDA break-even by Q4 2027.…more
$1.12-1.32%vs prev closeView filingShare - 9.9After-hours26.09.10 05:304Ownership
Bionano Genomics, Inc.
Bionano Genomics, Inc. executive Albert Luderer filed a Form 4 report regarding a change in beneficial ownership of securities as of September 4, 2026. This filing serves as an official notification of the insider's updated equity holdings.…more
$1.12-1.32%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.23Pre-market26.09.23 22:03#●●●#●●●
Bionano Genomics Expands Cancer Testing at Memorial Sloan Kettering
Bionano Genomics' optical genome mapping technology has been approved by New York State for use in blood cancer testing at Memorial Sloan Kettering. This expansion in clinical application marks a positive development for the company's diagnostic technology adoption.…more
$1.12-1.32%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.14Pre-market26.09.14 22:02
●●●●●●●● ●●●●● ●●●●●●
Bionano Genomics announced three new peer-reviewed studies demonstrating that its OGM technology effectively detects structural genomic alterations in high-risk blood cancers that standard methods miss. These findings reinforce the potential of OGM to improve prognostic accuracy and clinical decision-making for patients with hematologic malignancies.…more
$1.12-1.32%vs prev closeShareBenzinga - 9.14Pre-market26.09.14 22:00
●●●●●●●● ●●●●● ●●●●●●
Bionano Genomics announced three peer-reviewed studies demonstrating that its Optical Genome Mapping (OGM) technology detects clinically significant genomic alterations in blood cancers that standard testing often misses. This release focuses on academic validation of the technology's clinical utility rather than immediate commercial or financial impact.…more
$1.12-1.32%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report